Philips receives FDA premarket approval for its HeartStart OnSite and HeartStart Home defibrillators

Huge Two-Day Clean Sweep Auction July 24-25th. Click Here to Bid!

advertisement
Aktueller Standort:
>
>
> This Story

Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Cardiology Homepage

Abbott receives U.S. approval of next-generation MitraClip, bringing new enhancements to Abbott's leading MitraClip platform

Telehealth Technology to reduce hospital readmissions and improve outcomes for cardiac disease patients

FDA approves Bayer's Gadavist (gadobutrol) injection as first contrast agent for use in cardiac MR in adult CAD patients

New technology improves atrial fibrillation detection after stroke

New study of ultrasound enhancing agents in echocardiography reaffirms safety profile of LUMASON

Johns Hopkins Medicine researchers identify health conditions likely to be misdiagnosed

Team approach to cardiac care increases chance of surviving heart attack complications

Philips supports CNIC to shape the future of cardiac care

Cardiac arrest among hospitalized patients may be underestimated

RAPID receives registration approval in Japan

Philips receives FDA premarket approval for its HeartStart OnSite and HeartStart Home defibrillators

Press releases may be edited for formatting or style
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has approved the company's premarket approval (PMA) application for its HeartStart OnSite defibrillator [1] and HeartStart Home defibrillator [2], and the relevant supporting accessories, such as batteries and pad electrodes.

Philips' HeartStart OnSite and HeartStart Home defibrillators are the only over-the-counter automated external defibrillators (AEDs) available to consumers in the US, while the HeartStart Home defibrillator is the only AED specifically indicated for home environments.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



"We are committed to delivering high quality, innovative AEDs to provide personalized therapy to victims of sudden cardiac arrest," said Arman Voskerchyan, Business Leader Therapeutic Care at Philips. "Premarket approval for our HeartStart OnSite and HeartStart Home defibrillators, currently the only over-the-counter AEDs available in the US, reflects the robust work of our teams that delivered the strong and extensive technical, clinical and production data included in the PMA filing for these devices."

PMA for Philips' HeartStart OnSite and HeartStart Home defibrillators can be found here. These devices already had FDA 510(k) clearance, but are now subject to PMA.


About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2018 sales of EUR 18.1 billion and employs approximately 77,000 employees with sales and services in more than 100 countries.

Cardiology Homepage


You Must Be Logged In To Post A Comment